Skip to main
AARD

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Aardvark Therapeutics Inc's stock outlook remains favorable due to the recent FDA approval to lower the age eligibility for the Phase 3 HERO trial of its leading product candidate, ARD-101, expanding the patient population it can treat for hyperphagia associated with Prader-Willi Syndrome (PWS). The company is also strategically addressing the robust market for obesity treatments by developing oral therapeutics that could complement existing injectable therapies, positioning itself well within a competitive landscape. While the likelihood of success for ARD-101 has been adjusted to 50% and its potential launch delayed to 2029, the ongoing advancements and trial progress suggest strong underlying growth potential for Aardvark Therapeutics in the future.

Bears say

Aardvark Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily related to delays and uncertainties surrounding its Phase 3 clinical trial for ARD-101. Key risks include the potential for negative clinical results, regulatory hurdles that could prolong the approval process, and the possibility of unanticipated safety issues emerging, which collectively threaten the success of its flagship product targeting hyperphagia associated with Prader-Willi Syndrome (PWS). Additionally, the company has suspended guidance for the third-quarter HERO trial topline data, casting further doubt on its ability to meet key developmental milestones and maintain investor confidence.

AARD has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Buy based on their latest research and market trends.

According to 8 analysts, AARD has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.